Background: The mechanism for the contribution of eosinophils (EOS) to asthma pathophysiology is not fully understood. Genome-wide expression analysis of airway EOS by microarrays has been limited by the ability to generate high quality RNA from sufficient numbers of airway EOS.
Introduction
Recruitment of EOS to the lung has been reproducibly reported in allergic asthma [1] . While airway eosinophilia is commonly associated with increased risk for asthma exacerbation, severity, and poor prognosis [2] [3] [4] , the precise correlation of EOS to the pathophysiology of asthma remains controversial. Reduction of airway EOS is associated with decline of submucosal matrix protein deposition and airway smooth muscle hyperplasia [5, 6] suggesting that EOS contribute to airway remodeling. Through the production and release of pro-inflammatory mediators, EOS can amplify the expression of Th1, Th2, and Th17 cytokines and chemokines [7] [8] [9] indicating they play a role in the adaptive immune response. Recent trials of anti-IL-5 antibodies (mepolizumab and reslizumab) have shown benefits in asthma, particularly in reducing rates of exacerbations [10] [11] [12] .
One approach to understanding the biology of EOS in asthma is gene expression analysis by microarrays. Initial GeneChip analysis, which was performed using in vitro IL-5-activated circulating EOS, identified 66 genes that were up-regulated by IL-5 and predicted to have functions in adhesion, recruitment, activation and survival [13] . A subsequent study performed by our group showed that the expression of more than 200 genes was increased in vitro in IL-5-and GM-CSF-activated EOS, including the anti-apoptotic serine/threonine protein kinase Pim-1 [14, 15] . During their egress to the airway, in response to allergen, the phenotype of peripheral blood EOS changes dramatically [16] [17] [18] ; however, gene analysis with microarrays of airway EOS has not been explored.
We performed gene expression array analysis on sputum samples obtained following whole lung allergen challenge (WLAC), and on bronchoalveolar lavage (BAL) cells obtained following segmental bronchoprovocation with an allergen (SBPAg). These two in vivo allergen challenge models are wellestablished asthma models that lead to eosinophilic airway inflammation [19] [20] [21] . Typically SBP-Ag causes EOS to increase in the BAL from ,0.5% at baseline to ,70% after allergen challenge [9] while WLAC induces an increase of EOS in sputum from ,3% to ,10% [21] [22] [23] [24] . Therefore, we anticipated that analysis of total BAL and sputum cells by microarrays after SBPAg and WLAC and purified BAL EOS would facilitate identification of genes specifically expressed by airway EOS.
Materials and Methods

Subjects
The study was approved by the University of WisconsinMadison Health Sciences Institutional Review Board (IRB). Informed written consent was obtained from subjects prior to participation. Subjects had a history of mild atopic asthma as defined by at least one positive skin prick test and a history of allergen-induced asthma exacerbation with reversibility to albuterol .12% and/or a provocative concentration of methacholine producing a 20% fall in FEV 1 (PC 20 ) of ,8 mg/ml. None of the subjects were using inhaled or oral corticosteroids. 10 subjects finished the SBP-Ag protocol and 2 were excluded for lower percentage of EOS in BAL after SBP-Ag (,67%) or low purity of BAL EOS (,99%). 18 subjects completed the sputum protocol and 12 were excluded due to having ,500,000 cells, greater than 60% epithelial cells in the sputum, a greater than 2-fold difference in the percentage of epithelial cells pre-and post-WLAC, lack of RNA after extraction, or RNA integrity that was insufficient for microarrays.
Bronchoscopy, SBP-Ag, and Anti-IL-5 Administration
Detailed methods for bronchoscopy, SBP-Ag, and BAL cell preparation have previously been described [25] . A graded inhaled Ag challenge with Dermatophagoides farinae (Der p 1, dust mite), Felis catus domesticus (Fel d 1, cat) or Ambrosia artemisiifolia (Amb a 1, ragweed), obtained from Greer Laboratories (Lenoir, NC, USA) was performed to determine the participant's AgPD 20 (the provocative dose of Ag leading to a 20% fall in FEV 1 ). One month later, a baseline bronchoscopy with BAL (4 6 40 ml aliquots of sterile 0.9% NaCl) was performed followed by administration of Ag at a dose of 20% of the AgPD 20 into the lavaged segment (BAL V1, Figure 1 ). Bronchoscopy with BAL was repeated 48 h later (BAL V2, Figure 1 ). One month after the first SBP-Ag, a single dose of anti-IL-5 (750 mg, mepolizumab generously donated by GlaxoSmithKline) was administered intravenously to reduce the number of airway EOS. One month after mepolizumab treatment, the second SBP-Ag was performed with BAL immediately before (BAL V3) and 48 h later (BAL V4). Circulating EOS number was ,100 per ml at the time of the second SBP-Ag (BAL V3). BAL cells were assessed by hemocytometer using Turk's counting solution containing acetic acid and methylene blue and cell differentials were determined on cytospin preparations stained with the Wright-Giemsa-based Hema-3 (ThermoFisher/Thermo Scientific, Rockford, IL, USA). On BAL V2 (Figure 1 ), airway EOS were purified from BAL cells using a two-step Percoll gradient as previously described [8] . EOS were collected from the 1.085/1.100 g/ml interface.
Induced Sputum
Induced sputum was obtained as previously described [22] on visit 1 (sputum V1, Figure 1 ) and 48 h after a graded WLAC leading to a 20% fall in FEV 1 (sputum V2). Briefly, patients inhaled nebulized 3% saline for 5 minutes, rinsed out their mouth and then coughed with collection of the sputum produced. This was repeated a total of three times. The sputum was diluted 1:1 with PBS. After centrifugation, cytospins were prepared and stained with Giemsa to determine cell distributions. Cells were stored in Trizol solution for RNA purification.
RNA Preparation and Microarray Hybridization
Total RNA was extracted from BAL cells or purified BAL EOS using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), treated with DNase (RNase-free DNase kit, Qiagen), and RNA from BAL cells were submitted to the University of Wisconsin-Madison Gene Expression Center (Madison, WI) for labeling and hybridization. RNA quality and integrity was evaluated via Agilent 2100 Bioanalyzer platform (Agilent Technologies). Sense-strand cDNA was generated from total RNA using the Ambion Whole Transcript (WT) Target Expression Kit (Life Technologies, Grand Island, NY, USA). Fragmentation and labeling of the singlestranded cDNA was performed using the Affymetrix GeneChip WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA, USA). . Bronchoalveolar lavage and sputum timelines. Atopic mild asthmatics underwent bronchoalveolar lavage (BAL) followed by segmental challenge with an allergen (SBP-Ag) on visit 1 (BAL V1). 48 h later on visit 2 (BAL V2), BAL was performed at the site of the challenged segment. One month later, a single dose of mepolizumab was administered. One month after dosing, BALs were repeated both before and after SBPAg. BAL cells (BALC) were prepared on visits 1, 2, 3, and 4 and airway EOS (BALEOS) were purified on visit 2. For the induced sputum study, sputum collection was performed followed by a whole lung allergen challenge (WLAC) on visit 1 (sputum V1). Collection of a second induced sputum was done 48 h after WLAC on visit 2 (sputum V2). doi:10.1371/journal.pone.0067560.g001
The labeled cDNAs were hybridized to Human Gene ST 1.0 GeneChips (Affymetrix) according to the manufacturer's protocols.
Induced sputum samples were shipped to Miltenyi Biotech for RNA extraction using standard RNA Trizol extraction protocols. Sample integrity was evaluated via Agilent 2100 Bioanalyzer platform (Agilent Technologies). 50 ng of RNA was amplified and labeled using the Aglient Low Input Quick Amp Labeling Kit (AgilentTechnologies). Hybridization was performed using the Agilent Gene Expression Hybridization Kit to Agilent Whole Human Genome Oligo Microarrays 8X60K for microarray analyses. The Agilent Feature Extraction Software was used to read out and process the microarray image files.
Microarray Data Analysis
For BAL cells, raw data (CEL files) were uploaded into ArrayStar software version 4.0 (DNASTAR Inc., Madison, WI, USA) for normalization and statistical analysis. The robust multichip analysis (RMA) algorithm was used for background correction, quantile normalization and median polish summarization. Microarrays are deposited in the Gene Expression Omnibus repository (accession number: GSE46159). Four pairs of data comparisons that might reveal genes up-regulated in BAL cells after allergen challenge with or without mepolizumab were performed. The transcripts were filtered on the basis of $2-fold difference. The 99 genes up-regulated by SBP-Ag and decreased 1.5-fold by mepolizumab (Table S5) were determined using both the direct fold change between BAL V4 and V2 and the fold change between BAL V2 and V1 divided by the fold change between BAL V4 and V3 (see Figure 1 ).
For induced sputum samples, raw data files were analyzed using the Agilent Feature Extraction Software (FES) (Agilent Technologies). The software was used to determine feature intensities, perform background subtraction, reject outliers, and calculate statistical confidences. Microarrays are deposited in the Gene Expression Omnibus repository (accession number: GSE46238).To determine differential gene expression, the data outputted from FES was then analyzed using the Rosetta Resolver gene expression data analysis system (Rosetta Biosoftware). Ratios were calculated as control vs. sample, or before and after allergen challenge, by division of sample intensity through control signal intensity.
Real-time qPCR
The reverse transcription reaction was performed using the Superscript III system (Invitrogen/Life Technologies, Grand Island, NY, USA). mRNA expression was determined by qPCR using SYBR Green Master Mix (SABiosciences, Frederick, MD, USA) and human IL5RA, LTC4S, FFAR2, CNR2, ARAP3, DAPK2, PRSS33, TNFSF14, IL1R1 and FCER2 (CD23ß) forward and reverse specific primers (see Table S1 for primer sequences) were designed using Primer Express 3.0 (Applied Biosystems, Carlsbad, CA, USA) and blasted against the human genome to determine specificity using http://www.ncbi.nlm.nih. gov/tools/primer-blast. The reference gene, ß-glucuronidase ((GUSB), forward: caggacctgcgcacaagag, reverse: tcgcacagctggggtaag), was used to normalize the samples. Standard curves were performed and efficiencies were determined for each set of primers. Efficiencies ranged between 91 and 96%. Data are expressed as fold change using the comparative cycle threshold (DDCT) method as described previously [9] . The values presented in Figure 4 are fold change = (2 2DDCt ) compared to expression in BAL cells at V1 (before SBP-Ag).
Statistical Analyses
To compare expression of genes in total BAL cells and purified BAL EOS by qPCR, data were log transformed and analyzed using the Student's paired t-test. Statistical analyses were performed using SigmaPlot 11.0 software package.
Results
Gene Expression Analysis in BAL Cells 48 h after SBP-Ag by Microarrays
While less than 1% of BAL cells were EOS before SBP-Ag, they increased to 73.9% 64.2 (n = 8) of the total BAL cell population after SBP-Ag. After mepolizumab, SBP-Ag elicited a significant but much attenuated increase in EOS counts compared to before mepolizumab (34% 69 versus 73.9% 64.2; p,0.001, paired t test, n = 8) [26] . 2 of 8 subjects ( Figure 2 ) were randomly chosen for gene expression analysis using a whole human genome transcript microarray. For these 2 subjects, EOS constituted 72 and 74% of the BAL cells after SBP-Ag and were reduced to 24 and 39% of the BAL when SBP-Ag was performed after mepolizumab.
In total BAL cells, expression of 299 genes was up-regulated by more than 2-fold 48 h after SBP-Ag ( Figure 2 and Table S2 ). In both subjects, 22 transcripts were increased by more than 5-fold (Table S3 ) and 4 transcripts by more than 10-fold (ALOX15, CD1A, CD24 and FAM101B). The 299 genes up-regulated after SBP-Ag included marker genes for EOS (IL5RA, RNASE2, RNASE3, and SIGLEC8), and other genes well-known to be expressed by EOS (ADAM8, CCR3, CD69, CDA, GATA1, HRH4, ICAM3, IL1RL1, LTC4S, OXER1, P2RY2, PADI4, and SIGLEC10). Genes associated with lung remodeling were also found such as metalloproteinase genes (MMP12, MMP9), as well as some IL-13-induced chemokines (CCL13, CCL2) and Th2-associated genes (CCL22, FCER2, and IL1R2) [27] [28] [29] . While expression of genes coding for soluble mediators (e.g. cytokines) were unchanged, receptors for several mediators known to participate in lung fibrosis were up-regulated (CCR2, FGFR2, FLT1, IGF1R, IL1R1 and IL6R) [27, 29, 30] . 19 transcripts mostly expressed in dendritic cells, lymphocytes or mast cells (Table S4) , Swissprot research at http://www.uniprot.org/) were also included in the 299 transcripts. Further analysis using DAVID Bioinformatics Resources indicated that 31 genes have been previously associated with asthma, allergy or a pulmonary disease (DAVID Bioinformatics Resources 6.7; National Institute of Allergy and Infectious Diseases (NIAID), NIH) (Table S5) . 99 (33.1%) of the 299 transcripts elevated by more than 2-fold in BAL cells after SBP-Ag were decreased by more than 1.5-fold after reduction of EOS by mepolizumab (Table S6 ). Of note, 1.5-versus 2-fold reduction was chosen because mepolizumab decreased EOS percentage in BAL cells by ,50%. Among the 99 genes whose expression was down-regulated after SBP-Ag are the well-known EOS-specific genes (IL5RA, RNASE2, RNASE3 and SIGLEC8) and all the other transcripts mentioned above as previously known to be expressed by EOS (ADAM8, CD69, GATA1, HRH4, ICAM3, IL1RL1, LTC4S, OXER1, P2RY2, PADI4 and SIGLEC10) except for CCR3. In addition, other genes that are not known to be expressed by EOS were downregulated by mepolizumab. Whether these genes are expressed by other cell types (lymphocytes, dendritic cells, macrophages, or mast cells) that are affected directly or indirectly by the lack of IL-5 or the reduction of EOS or directly expressed by EOS is not known.
Identification of EOS-associated Genes by Microarray Using Induced Sputum after WLAC
Sputum cells from 6 subjects were analyzed by a whole genome transcript microarray. WLAC increased the percentage of EOS in sputum from 2.0 to 8.2% (p,0.001). Marker genes for EOS (RNASE2, RNASE3, IL5RA and SIGLEC8) were increased by more than 2-fold after WLAC in 3 of the 6 subjects involved in this analysis. Sputum samples from these 3 individuals allowed us to establish a list of 365 EOS-associated genes whose expression was increased by more than 1.5-fold after WLAC (Table 1 ). In addition to the original EOS markers (RNASE2, RNASE3, IL5RA and SIGLEC8), the 365 transcripts (Table 1) included some other well-known genes expressed by EOS. In fact, 11 of the 13 genes (ADAM8, CCR3, CD69, CDA, HRH4, ICAM3, IL1RL1, LTC4S, P2RY2, PADI4 and SIGLEC10) known to be expressed by EOS and up-regulated in BAL cells after SBP-Ag (Table S2) were also seen in sputum after WLAC.
Identification of Airway EOS Gene Expression
We have utilized 3 airway models that either augmented or reduced the EOS population, and defined genes concomitantly expressed with markers of EOS genes in the context of allergen challenges in vivo. Figure 3 shows that 168 (111+57) (46%) of the 365 EOS-associated genes in sputum were also identified in the 299 genes up-regulated in BAL cells. This suggests that despite distinct anatomical sites and provocative protocols, infiltrating EOS express a consistent group of transcripts. Furthermore, the intersection of these 2 sets with the genes decreased by mepolizumab identified a group of 57 genes ( Figure 3 and Table 2 ). We propose that this intersection represents a stringent selection for gene expression by airway EOS. A literature search in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) indicates that only 16 of the 57 genes (28%) have been previously linked to EOS. Therefore, 41 genes (.70%) in this subset have not previously been associated with EOS.
Validation of the Airway EOS-associated Genes
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and defense response (6 genes), and receptors for a variety of stimuli such as carbohydrates and nucleotides (15 genes) (Table  S7 ).
Discussion
We have used a unique approach combining 3 whole genome expression microarrays (sputum cells after WLAC, BAL cells after SBP-Ag, and BAL cells after mepolizumab and SBP-Ag) to identify 57 genes highly expressed by airway EOS after an allergen challenge. We demonstrated that EOS are likely the main source of these 57 genes expressed by total BAL cells. The 57 genes included genes such as CD69, IL5RA, LTC4S, RNASE2, RNASE3, SIGLEC8, ADAM8, CDA, ICAM3, IL1RL1 (ST2), and P2RY2 that are known to be expressed in EOS, and other genes not previously linked to EOS. Cluster analysis indicated these genes might have an impact on EOS migration and activation, as well as the innate and adaptive immune responses.
Of the 57 transcripts associated with airway EOS, 16 have been previously detected in circulating EOS, including IL1RL1, CNR2, and FFAR2. IL1RL1 (also known as ST2) is the receptor for IL-33, a cytokine that is released following epithelial damage during an allergic reaction. IL-33 can activate CD4 + T cells, type-2 innate lymphoid cells, and mast cells, as well as EOS [33] . The function of IL-33 on circulating EOS includes induction of degranulation, cytokine release, and increased survival. In vivo, blockade of the IL-33/IL1RL1 pathway reduces allergic inflammation and airway responsiveness [34] . Our study suggests that EOS might be the main source of IL-33 receptor among the airway inflammatory cells present after SBP-Ag, and EOS could contribute to IL-33-mediated effects in allergic asthma. CNR2 (also called CB2 receptor) is the cannabinoid receptor expressed in lymphoid organs [35] . CNR2 is known to be expressed by circulating EOS, and an endogenous ligand (2-arachidonoylglycerol) induces EOS migration [36] . In mice, genetic deletion of Cnr2 exacerbated contact allergic inflammation and influenza-induced excessive airway injury possibly via induction of pro-inflammatory and proremodeling mediators (IL-17, IL-13, TNF-a, GM-CSF) [37, 38] . CNR2 agonists reduced bronchoconstriction, mast cell degranulation and pulmonary inflammation in guinea pigs [39] . Another endogenous CNR2 ligand, anandamide is increased in BAL fluids after SBP-Ag, and correlated with the number of EOS in the airway [40] . Finally, FFAR2 expression by EOS has only been reported once [32] . FFAR2 (also known as GPR43) is a lipid Gprotein coupled receptor for short-chain fatty acids that is produced by bacteria after fermentation of dietary fibers. Interestingly, the lack of FFAR2 led to unresolved inflammation in several animal models of inflammation, including allergeninduced airway inflammation [32] , suggesting FFAR2 activation by short-chain fatty acids would be beneficial to reduce asthma.
One example of potentially novel EOS-derived mediators is TNFSF14 (also called LIGHT), a membrane-expressed or secreted protein that interacts with TNFRSF14 membrane receptor (HVEM), and was characterized as a co-stimulatory ligand for lymphoid cells [41] . As most of the co-stimulatory members of the TNF/TNFR superfamily, TNFSF14 has been studied for its impact on autoimmune disease and transplant rejection [41] . More recently, LIGHT has been implicated in induction of airway fibrosis and smooth muscle hyperplasia via TGF-ß and IL-13 production in an allergic animal model [42] . Interestingly, in human sputum, LIGHT protein level has been associated with lower lung function (FEV 1% predicted) [43] .
Another example of novel mediators in human EOS is PGLYRP1 or PGRP-S (also called Tag7), which recognizes bacterial peptidoglycan and has an antibacterial function [44] . PGLYRP1 is a 21Kd protein with a signal peptide for secretion. Table 2 . 57 genes upregulated in BAL cells after SBP-AG, down-regulated when SBP-Ag was performed following mepolizumab, and part of the EOS-associated genes in sputum after WLAC. GPR97  NHSL2  RNASE2  TRPM6   CASS4  DGKD  ICAM3  P2RY2  RNASE3  TSPAN18   CD300LB  EMR4P  IFITM1  PADI2  SIGLEC10  VSTM1   CD69  FAM101B IL1RL1  PADI4 While PGLYRP1 has not been described in human EOS, bovine and mouse EOS are known to express and store the bovine and murine ortholog of PGLYRP1 [45, 46] . In addition, to its antimicrobial function, several mouse models using PGLYRP1 knock-out, have demonstrated both an anti-inflammatory role for PGLYRP1 that down-regulated the production of type-1 cytokines and chemokines [47] , and a pro-inflammatory role in atopic dermatitis, contact dermatitis, and pulmonary inflammation models promoting the Th1, Th2 and Th17 response [48, 49] . Also, through its interaction with Hsp70 on cytotoxic lymphocytes, PGLYRP1 possesses anti-tumor cell activity [50] . Another intriguing gene is PRSS33 (also called Protease EOS). This member of the trypsin-like serine proteases has been described to be predominantly produced by macrophages [51] . However, an international patent has described PRSS33 as expressed by EOS as well (Pub. No.: WO/2001/016290). Proteases have crucial roles in maintaining homeostasis and regulating inflammation and immune reactions, thus their expression in EOS is under active investigation. For instance, PRSS21 (esp-1) has been found in EOS but not in neutrophils [52] , and we have shown very recently that EOS could generate high amounts of another protease, MMP-9 [53] . Yet, the production of PRSS33 by human EOS remains uncertain.
There is little overlap between airway EOS genes described in the present study and previous microarrays using in vitro activated blood EOS. In vitro, IL-5 induced the up-regulation of CD69 by blood EOS [13, 14] . Surprisingly, CD69 was the only common gene between our 57 EOS-associated genes and the genes upregulated by IL-5 or GM-CSF in these 2 previous studies. This suggests that a short-term in vitro activation using IL-5 or GM-CSF might not be an adequate model to reflect in vivo EOS activation after an allergen challenge. In addition, the present study analyzed the presence of genes associated with eosinophilia while the 2 previous studies analyzed genes that are cytokine-induced. Thus, in addition to their exposure to cytokines, airway EOS likely become activated as a result of their transmigration out of the blood and through the tissues. Future studies will be required to determine if the 57 genes are inducible or constitutively expressed by airway EOS. Comparison of gene expression in airway EOS after allergen challenge with blood EOS obtained from individuals who do not receive challenge would provide information on the inducible versus constitutive expression of these genes.
In a study by Nakajima et al. [54] , microarray analysis examined EOS-specific transcripts by comparison to other nucleated peripheral blood cells. Among the 30 EOS-specific genes, 3 were present in our list of 57 genes (RNASE2, IL5RA and CNR2). 11 of the 30 genes were also up-regulated in our BAL cells after SBP-Ag including GPR44, ALOX15, P2RY14, IDO1, ADORA3, CAMK1, CCR3 and P2RY10; while 10 of the 30 genes were part of the EOS-associated genes in induced sputum (CLC, PLAUR, MARCKSL1, P2RY14, CAMK1, CCR3, and OLIG2).
Gene expression analysis by microarrays has been previously performed on bronchial biopsies from asthmatic patients and on airway epithelial cells [55, 56] but microarray analysis using BAL cells after in vivo challenge has not been reported. In our whole genome expression analysis, 299 genes were up-regulated after SBP-Ag in BAL cells. Cluster analysis by DAVID Bioinformatics Resources identified 36 genes involved in defense, immune, or wound-healing responses, 32 genes implicated in cell adhesion or locomotion, 23 genes that regulate transcription, 21 genes associated with apoptosis and 12 genes that are part of the second-messenger-mediated signaling. Importantly, the EOS markers (RNASE2 and RNASE3, also called EDN and ECP) as well as 15 other well-known EOS-associated genes were upregulated concomitantly with EOS accumulation in the airway following SBP-Ag. Of these 17 genes, all but CCR3 were decreased by the mepolizumab infusion. Among the 13 genes up-regulated by SBP-Ag and related to lung remodeling (CCL2, CCL13, CCL22, CCR2, FCER2, FGFR2, FLT1, IGF1R, IL1R1, IL1R2, IL6R, MMP9 and MMP12), 11 of them were unchanged following mepolizumab. This suggests that in this model mepolizumab did not impact expression of remodeling-associated genes.
Potential limitations of this study include the inability to assess gene expression in non-hematopoietic airway cells (including epithelial cells) or to detect by microarray transcripts, such as cytokines, that are in low abundance. Unlike microarray analysis, qPCR allowed detection of IL-13 and IL-17A in BAL after SBPAg [9] . This suggests that some genes might have been excluded from the final eosinophilic genes and that the list of 57 genes is not an exhaustive inventory. Finally, it is important to note that a portion of the genes that are not affected by mepolizumab may in fact represent genes associated with a distinct phenotype of eosinophils that were recruited to or differentiated in the airway following administration of mepolizumab.
In conclusion, we have identified 57 genes highly expressed in vivo by airway EOS (BAL and sputum). Most of the 57 genes have not been previously studied in EOS and are important candidates to understand tissue EOS biology and to find new targets for therapies associated with an excessive eosinophilic response. 
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